Development of an exploratory prediction model for preoperative CK19 expression in esophageal cancer driven by radiomics and machine learning

Abstract

Background Esophageal cancer ranks among the most lethal malignancies worldwide, particularly prevalent in the Guangdong–Chaoshan region of China due to regional dietary habits. Cytokeratin 19 (CK19) is an important immunohistochemical marker reflecting tumor invasiveness and metastatic potential; however, noninvasive preoperative prediction of CK19 expression remains unavailable. This study aimed to develop a CT-based radiomics model combined with machine learning to predict CK19 expression preoperatively. Methods This study included 134 patients with primary esophageal cancer. All patients underwent enhanced CT scans before surgery, and CK19 expression was evaluated by pathological analysis after surgery. Radiomics technology was used to extract multidimensional image features including shape, texture, and first-order features from CT images. A prediction model was established by combining machine learning models such as gradient boosted decision tree (GBDT), random forest (RF), extreme gradient boosting (XGB), and lightweight gradient boosting machine (LGBM), and the interpretability of the model was analyzed by SHAP value. Results The random forest model showed relatively higher accuracy and precision among the compared models, with an AUC value of 0.6765 and an accuracy of 0.8293. GBDT demonstrated a more balanced performance (AUC: 0.6597), while XGB (AUC: 0.6744) and LGBM (AUC: 0.6807) showed comparable but overall slightly lower discriminative ability. Feature importance analysis showed that the features after wavelet transformation made a significant contribution to the prediction results. The results verified the potential of radiomics combined with machine learning technology in the preoperative prediction of CK19 expression. Conclusion This study developed a preoperative noninvasive prediction model based on radiomics and machine learning, which showed modest predictive performance in an exploratory setting in the evaluation of CK19 markers in patients with esophageal cancer, may provide preliminary support for further exploration in precision medicine. In the future, the clinical applicability of this model needs to be further verified and its promotion and application in a larger population needs to be optimized.